Postexposure treatment with nirmatrelvir-ritonavir doesn't reduce risk of getting COVID-19.

Study finds that postexposure prophylaxis with nirmatrelvir-ritonavir does not reduce risk of COVID-19 infection, according to a recent report.

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic SARS-CoV-2 infection.
A study found no significant difference in the development of COVID-19 between those who received the medication and those who received a placebo.
Adverse events were similar in all trial groups.
Results showed that nirmatrelvir-ritonavir did not significantly reduce the risk of SARS-CoV-2 infection among household contacts of COVID-19 patients.
The authors suggest that nirmatrelvir-ritonavir given as postexposure prophylaxis did not provide substantial protection against COVID-19 in this study.

Postexposure treatment with nirmatrelvir-ritonavir doesn’t reduce risk of getting COVID-19.